Prognostic significance of LOXL2 enzyme activity in primary myelofibrosis Authors: Guoqing Lv, Wenting Lv Published: 2024 ABSTRACT Primary myelofibrosis (PMF) is characterized by bone marrow fibrosis, but the underlying molecular mechanisms remain incompletely understood. Here, we investigated the role of lysyl oxidase-like 2 (LOXL2), an enzyme involved in extracellular matrix remodeling, in PMF pathogenesis. Analysis of bone marrow cells from PMF patients revealed significantly elevated LOXL2 mRNA expression compared to healthy controls, which was further validated using 2 independent Gene Expression Omnibus datasets (GSE26049 and GSE12234). Serum LOXL2 protein levels were markedly increased in PMF patients (n = 38) compared to controls (n = 15) (P < .01), accompanied by significantly enhanced enzymatic activity (P < .05). Clinical analysis demonstrated that high LOXL2 enzyme activity correlated with adverse clinical features, including higher risk scores in both International Prognostic Scoring System (P = .029) and Dynamic International Prognostic Scoring System (P = .012) systems, and increased peripheral blood blast percentages (≥1%, P = .019). Notably, elevated LOXL2 enzyme activity emerged as an independent adverse prognostic factor in multivariate analysis. Gene set enrichment analysis revealed LOXL2’s association with multiple biological processes, including extracellular matrix remodeling, inflammatory responses, and JAK-STAT signaling pathways. Using CellMiner drug prediction analysis, we identified several FDA-approved drugs, particularly kinase inhibitors, as potential LOXL2-targeting therapeutics. Our findings demonstrate LOXL2’s critical role in PMF pathogenesis and suggest its potential as both a prognostic marker and therapeutic target in PMF treatment. 1. Introduction Primary myelofibrosis (PMF) is a malignant tumor of the hematologic system, primarily affecting middle-aged and elderly individuals. It is characterized by the presence of fibrosis in the bone marrow and has a poor prognosis with high mortality rates.[1–7] The detailed mechanism of PMF is still not fully understood, although the JAK2V617F mutation is the most common mutation associated with this condition. The JAK2V617F mutation leads to the activation of the JAK-STAT signaling pathway, which plays a crucial role in the pathogenesis of PMF. Consequently, JAK2 inhibitors have become an important treatment option for this disease. Clinical studies have demonstrated that JAK2 inhibitors can effectively improve the symptoms and signs of PMF, enhancing the quality of life for affected patients. However, it is important to note that JAK2 inhibitors do not selectively inhibit the proliferation of malignant clonal cells and do not eradicate the malignant clones or reduce the clone load of the JAK2V617F mutation. Additionally, they do not restore normal hematopoiesis and can ultimately alter the biological properties of PMF, leading to rapid relapse in some patients upon discontinuation of therapy.[2,8,9] Therefore, it is evident that there may be other pathogenic mechanisms in PMF, aside from the JAK2V617F mutation. One such mechanism involves the presence of fibrosis in the bone marrow. Recent studies have highlighted the role of lysyl oxidase, a key enzyme in the fibrosis process, as a potential target for fibrosis treatment in various conditions, including pulmonary fibrosis and hepatic fibrosis. Specifically, lysyl oxidase-like 2 (LOXL2) has been identified as a critical enzyme involved in extracellular matrix (ECM) remodeling and fibrosis regulation. LOXL2 catalyzes the deamination and oxidation of lysine residues in collagen fibers and elastin, promoting covalent cross-linking between these molecules and playing a significant role in the reconstruction of the ECM. This process, in turn, alters the tumor microenvironment and influences tumor survival, proliferation, apoptosis, migration, invasion, and metastasis.[10–13] In our study, we aimed to investigate the expression of LOXL2 in PMF tissue cells and assess its enzymatic activity. Additionally, we utilized a bioinformatics approach to explore the molecular mechanisms underlying the role of LOXL2 in PMF. 2. Materials and methods 2.1. Study population and ethics In this study, we enrolled 38 patients with PMF who were admitted to the First Affiliated Hospital of Xinxiang Medical University between January 2020 and December 2023. Additionally, 15 healthy individuals were recruited as controls. All PMF diagnoses were established in accordance with both the National comprehensive cancer network guidelines and the Chinese PMF diagnosis and treatment guidelines. Patient follow-up was conducted from the initial diagnosis date until either death or the study endpoint in December 2023. This research was conducted in strict adherence to the principles outlined in the Declaration of Helsinki. The study protocol received formal approval from the Clinical Research Ethics Committee of the First Affiliated Hospital of Xinxiang Medical University (Approval No.: 2020/2020126). Prior to participation, all patients and healthy volunteers provided written informed consent after receiving detailed information about the study objectives and procedures (Table 1). Table 1Clinical features of primary myelofibrosis.VariablesNo. Gender Female16 (42%)Male22 (58%)Median age, years (range)68 (45–78) IPSS Low7 (18%)Intermediate-113 (34%)Intermediate-215 (39%)High3 (8%) DIPSS Low9 (24%)Intermediate-113 (34%)Intermediate-214 (37%)High2 (5%) JAK2V617F wt15 (39%)Mutation23 (61%)WBC (×109, range)9.2 (0.53–35.2)Hb (g/dL, range)93 (39–164)Platelet (×109, range)146 (24–495)Blood blasts (bone marrow)%2.3 (0–18)DIPSS = Dynamic International Prognostic Scoring System, Hb = hemoglobin, IPSS = International Prognostic Scoring System, WBC = white blood cell, wt = wildtype. Clinical features of primary myelofibrosis. DIPSS = Dynamic International Prognostic Scoring System, Hb = hemoglobin, IPSS = International Prognostic Scoring System, WBC = white blood cell, wt = wildtype. 2.2. Peripheral blood serum collection Peripheral blood samples (4–6 mL) were collected from patients with PMF and healthy controls via standard venipuncture. Samples were centrifuged at 1500 rpm for 15 minutes, and the supernatant serum was carefully separated and stored in labeled cryovials at −80°C for further analysis. 2.3. Isolation of bone marrow mononuclear cells Fresh bone marrow aspirates (4–6 mL) were collected and centrifuged at 2500 rpm for 15 minutes at 4°C. The supernatant was discarded to isolate the cell pellet. Red blood cells were lysed according to standard operating procedures by adding red blood cell lysis buffer to the pellet, followed by gentle vortexing and brief incubation to ensure complete lysis, resulting in the isolation of bone marrow mononuclear cells. Trizol reagent was then added to the bone marrow mononuclear cells for RNA extraction, preparing the isolated mononuclear cells for subsequent analyses. 2.4. Real-time PCR analysis Total RNA was extracted from the isolated bone marrow mononuclear cells using a commercially available RNA extraction kit, following the manufacturer’s instructions. Real-time PCR was performed to quantify the expression levels of the loxl2 gene. Specific primers for LOXL2 were designed based on our previously published sequences in the literature.[14,15] 2.5. LOXL2 protein concentration assay The LOXL2 ELISA kit (Santa Cruz Biotechnology Inc., Dallas, TX) was used to determine the concentration of LOXL2 in the serum samples of PMF patients and healthy controls. 2.6. LOXL2 enzyme activity LOXL2 enzyme activity was measured by using the Amplex® Red assay kit (Invitrogen Life, Carlsbad, CA). The enzyme activity of LOXL2 in the samples was determined by following the standard operating procedures of the Amplex® Red assay.[15] 2.7. Gene expression profiles Gene expression profiles were obtained from the Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) database, and GSE26049 and GSE12234 were selected to download the gene expression profiles of PMF, both of which contained PMF patients and healthy controls. 2.8. Gene set enrichment analysis (GSEA)[16] GSEA was performed by using GSEA version 4.3.3 software to analyze the gene expression data in the gene expression profiles GSE26049 and GSE12234 of PMF data. 2.9. Identification of potential molecular targeted drugs using the CellMiner software[17] The CellMiner software is a bioinformatics tool used to analyze the interaction between drugs and genes, and predict the efficacy of specific drugs based on gene expression patterns. Through in-depth analysis using the CellMiner software, potential targeted drugs for the LOXL2 gene were explored. 2.10. Statistical analysis Patient characteristics were summarized using descriptive statistics, with continuous variables expressed as median and range. For comparative analyses, we employed standard statistical methods based on data distribution patterns. Normally distributed variables were analyzed using t tests, while non-normally distributed data were evaluated using Mann–Whitney U tests. For categorical variables, we utilized χ2 or Fisher exact tests as appropriate. Overall survival, measured from diagnosis to death or last follow-up, served as the primary endpoint. Survival analyses were conducted using Kaplan–Meier curves with log-rank tests for group comparisons. We developed multivariate Cox proportional hazard models using backward elimination to identify independent prognostic factors. All statistical analyses were two-sided with significance defined as P < .05, performed using current versions of R, SPSS, and GraphPad Prism software packages. 3. Result 3.1. Expression analysis of LOXL2 mRNA in PMF To investigate the expression pattern of LOXL2 in PMF, we first analyzed LOXL2 mRNA levels in bone marrow cells from PMF patients and healthy controls. Our analysis revealed significantly elevated LOXL2 mRNA expression in PMF bone marrow cells compared to normal controls (P < .05), suggesting a potential role of LOXL2 in PMF pathogenesis (Fig. 1A). The expression of LOXL2 mRNA in PMF. LOXL2 = lysyl oxidase-like 2, PMF = primary myelofibrosis. To validate these findings, we further analyzed 2 independent publicly available gene expression datasets from the NCBI Gene Expression Omnibus database. Analysis of the PMF gene expression profiling data from GSE26049 and GSE12234 consistently demonstrated upregulation of LOXL2 mRNA in PMF samples (P < .05) (Fig. 1B and C). 3.2. Serum LOXL2 protein concentrations in PMF Our study aimed to further understand the role of LOXL2 in PMF. As LOXL2 is a secretory protein, we hypothesized that it may play a role in the remodeling and fibrosis processes of the ECM during disease progression. To validate this hypothesis, we utilized the LOXL2 ELISA assay kit, which allows for quantitative measurement of LOXL2 protein concentrations in serum. We selected 38 patients with PMF and 15 healthy controls. By comparing the LOXL2 protein concentrations between the 2 groups, we observed a significant increase in LOXL2 protein concentrations in patients with PMF (P < .01) (Fig. 2A). Serum LOXL2 protein level of PMF (A); LOXL2 enzyme activity in PMF (B). LOXL2 = lysyl oxidase-like 2, PMF = primary myelofibrosis. 3.3. Enzymatic activity of LOXL2 LOXL2 was a number of lysyl oxidase family and its enzyme activity might be associated with the remodeling and fibrosis processes of the ECM. The differences in LOXL2 enzyme activity between the PMF group and the healthy control group were compared. and found that the enzyme activity of LOXL2 was almost undetectable in the healthy control group, while in the PMF group, the LOXL2 enzyme activity was significantly increased in the PMF group (P < .05) (Fig. 2B). These findings further confirm the importance of LOXL2 in the fibrosis process. The elevated LOXL2 enzyme activity may be associated with the fibrosis processes of the disease. 3.4. Clinical characteristics associated with LOXL2 enzyme activity in PMF To investigate the clinical significance of LOXL2 enzyme activity in PMF, we conducted a comprehensive analysis by stratifying patients into high and low LOXL2 enzyme activity subgroups. This stratification enabled us to examine the associations between LOXL2 expression levels and various clinical parameters. Our analysis revealed several significant correlations between LOXL2 enzyme activity and disease severity indicators. Notably, patients in the high LOXL2 enzyme activity subgroup demonstrated significantly higher risk profiles according to well-established prognostic scoring systems. Specifically, we observed a markedly increased prevalence of high and Intermediate-2 risk scores in both the International Prognostic Scoring System (IPSS) (P = .029) and the Dynamic International Prognostic Scoring System (DIPSS) (P = .012) among these patients. A particularly striking finding was the significant association between elevated LOXL2 enzyme activity and peripheral blood blast percentages. The high LOXL2 subgroup showed a substantially higher proportion of patients with blood blasts ≥ 1% (P = .019), suggesting a potential relationship between LOXL2 activity and disease progression. Interestingly, our analysis revealed no significant correlations between LOXL2 enzyme activity and several other clinical parameters, including: Demographic factors (age and gender), hematological parameters (white blood cell count, platelet count, and hemoglobin levels), molecular markers (JAK2V617F mutation status). These findings suggest that LOXL2 enzyme activity may represent an independent prognostic marker in PMF, particularly associated with advanced disease features and higher risk categories (Tables 1 and 2). Table 2Clinical features of LOXL2 enzyme activity.VariablesNo.LOXL2 enzyme activityP-valueLowHigh Gender .743Female169 (47.3)7 (36.8)Male2210 (52.7)12 (63.2) Age .08>652615 (78.9)11 (57.9)≤65124 (21.1)8 (42.1) IPSS .029 Low77 (36.8)0Intermediate-1138 (42.1)5 (26.3)Intermediate-2154 (21.1)11 (57.9)High303 (15.8) DIPSS .012 Low99 (47.4)0Intermediate-1138 (42.1)5 (26.3)Intermediate-2142 (10.5)12 (63.2)High202 (10.5) JAK2V617F .295wt158(42.1)7(36.8)mutation2311(57.9)12(63.2)WBC (×109, range)388.8 (0.53–35.2)9.7 (0.6–26.9).363Hb (g/dL, range)3896.1 (39–156)90.5 (42–164).271Platelet (×109, range)38111.4 (24–495)162.1 (36–382).492 Blood blasts at least 1% 25 6 19 .019 DIPSS = Dynamic International Prognostic Scoring System, Hb = hemoglobin, IPSS = International Prognostic Scoring System, LOXL2 = lysyl oxidase-like 2, WBC = white blood cell, wt = wildtype. Clinical features of LOXL2 enzyme activity. DIPSS = Dynamic International Prognostic Scoring System, Hb = hemoglobin, IPSS = International Prognostic Scoring System, LOXL2 = lysyl oxidase-like 2, WBC = white blood cell, wt = wildtype. 3.5. Prognostic significance of LOXL2 enzyme activity in PMF Based on LOXL2 enzyme activity, the patients were divided into 2 groups: a high-expression group and a low-expression group. Our findings revealed a significant correlation between LOXL2 enzyme activity levels and the prognosis of patients with PMF. Specifically, patients exhibiting high LOXL2 enzyme activity had a poorer prognosis, while those with low LOXL2 enzyme activity demonstrated a more favorable outcome (P = .042) (Fig. 3). Kaplan–Meier OS curves of the LOXL2 enzyme activity in PMF. LOXL2 = lysyl oxidase-like 2, OS = overall survival, PMF = primary myelofibrosis. Cox regression analysis further identified several poor prognostic factors, including high LOXL2 enzyme activity, a high proportion of blast cells in the bone marrow, and elevated scores on the IPSS and the DIPSS (P < .05). Notably, high LOXL2 enzyme activity was established as an independent adverse prognostic factor (P < .05). In contrast, factors such as gender, age, white blood cell count, hemoglobin levels, and platelet count did not show a significant relationship with patient prognosis (Table 3). Table 3Univariate and multivariate analyses of OS in PMF patients.VariablesUnivariate analysisMultivariate analysisHR (95% CI)P valueHR (95% CI)P valueGender1.03 (0.83–1.27).7Age(≥60 vs < 60 y)1.19 (0.79–1.52).2IPSS(Intermediate, High vs Low)3.51 (1.79–4.72).013DIPSS(Intermediate, High vs Low)3.95 (1.36–5.52).0171.68 (1.21–3.55).013JAK2V617F(mutation vs wt)0.93 (0.89–1.34).9WBC1.17 (0.56–1.24).6Hb0.62 (0.44–1.38).2Platelet0.85 (0.65–1.61).5Blood blasts (bone marrow)%(≥10% vs < 10%)2.33 (1.36–3.57).0241.46 (1.13–3.16).022Enzymatic activity of LOXL2(high vs Low)1.98 (1.18–3.51).0191.75 (1.13–2.65).039DIPSS = Dynamic International Prognostic Scoring System, Hb = hemoglobin, IPSS = International Prognostic Scoring System, LOXL2 = lysyl oxidase-like 2, OS = overall survival, PMF = primary myelofibrosis, WBC = white blood cell, wt = wildtype. Univariate and multivariate analyses of OS in PMF patients. DIPSS = Dynamic International Prognostic Scoring System, Hb = hemoglobin, IPSS = International Prognostic Scoring System, LOXL2 = lysyl oxidase-like 2, OS = overall survival, PMF = primary myelofibrosis, WBC = white blood cell, wt = wildtype. 3.6. GSEA reveals multiple pathways associated with LOXL2 in PMF GSEA was performed to investigate the biological pathways associated with LOXL2 in PMF. Our analysis revealed significant enrichment in multiple key pathways that can be categorized into several major biological processes. The most significantly enriched pathways were related to ECM organization and tissue remodeling. Specifically, ECM receptor interaction, focal adhesion, and regulation of actin cytoskeleton pathways showed strong positive enrichment. Additionally, the TGF-beta signaling pathway and epithelial-mesenchymal transition were significantly upregulated, supporting LOXL2’s role in tissue fibrosis. Inflammatory and immune response pathways demonstrated substantial enrichment, including interferon gamma response, interferon alpha response, and inflammatory response pathways. Notably, the IL6-JAK-STAT3 and IL2-STAT5 signaling pathways were also significantly enriched, suggesting LOXL2’s involvement in inflammatory signaling cascades within the bone marrow microenvironment. Analysis of cell signaling networks revealed significant enrichment in several cancer-related pathways. The MAPK signaling pathway and JAK-STAT signaling pathway showed positive enrichment, along with broader pathways in cancer. These findings indicate LOXL2’s potential role in disease progression and cellular transformation in PMF. Vascular system-related pathways were also prominently represented in our analysis. We observed significant enrichment in angiogenesis, complement and coagulation cascades, and leukocyte transendothelial migration pathways. These results suggest LOXL2’s involvement in vascular remodeling and cellular trafficking within the bone marrow niche. Furthermore, cellular stress response pathways showed significant enrichment, including hypoxia response, UV response downregulation, and glycolysis. The enrichment of apoptosis-related pathways suggests LOXL2’s role in cellular adaptation to stress conditions within the PMF microenvironment. Collectively, these results demonstrate that LOXL2 is associated with multiple biological processes in PMF, extending beyond its conventional role in ECM modification. The enriched pathways span from matrix remodeling to inflammation, vascular function, and cellular stress response, suggesting LOXL2’s complex role in PMF pathogenesis (Tables 4 and 5). Table 4KEGG analysis with Gene set enrichment analysis (GSEA).NAMEESNESNOM P-valueFDRECM_RECEPTOR_INTERACTION0.642.7400FOCAL_ADHESION0.532.600CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION0.422.0400.003REGULATION_OF_ACTIN_CYTOSKELETON0.422.0100.004COMPLEMENT_AND_COAGULATION_CASCADES0.441.78.0020.033GAP_JUNCTION0.431.7600.035CYTOSOLIC_DNA_SENSING_PATHWAY0.481.75.0040.034MAPK_SIGNALING_PATHWAY0.351.7300.031PATHWAYS_IN_CANCER0.331.6800.042LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION0.341.51.0190.131JAK_STAT_SIGNALING_PATHWAY0.321.46.010.158TGF_BETA_SIGNALING_PATHWAY0.351.45.030.169ES = Enrichment Score, FDR = false discovery rate, KEGG = Kyoto Encyclopedia of Genes and Genomes, NES = Normalized Enrichment Score. KEGG analysis with Gene set enrichment analysis (GSEA). ES = Enrichment Score, FDR = false discovery rate, KEGG = Kyoto Encyclopedia of Genes and Genomes, NES = Normalized Enrichment Score. Table 5Hallmark analysis with Gene set enrichment analysis (GSEA).NAMEESNESNOM P-valueFDREPITHELIAL_MESENCHYMAL_TRANSITION0.783.800HYPOXIA0.542.5700UV_RESPONSE_DN0.532.4900APICAL_JUNCTION0.492.3500TNFA_SIGNALING_VIA_NFKB0.482.300ANGIOGENESIS0.612.1700INTERFERON_GAMMA_RESPONSE0.432.0200.001COAGULATION0.421.9700.001INFLAMMATORY_RESPONSE0.41.9100.001INTERFERON_ALPHA_RESPONSE0.461.8700.003IL6_JAK_STAT3_SIGNALING0.411.78.0020.004TGF_BETA_SIGNALING0.441.7.0040.007GLYCOLYSIS0.351.6500.01APOPTOSIS0.331.56.0040.02COMPLEMENT0.321.55.0020.02IL2_STAT5_SIGNALING0.281.34.030.091ES = Enrichment Score, FDR = false discovery rate, NES = Normalized Enrichment Score. Hallmark analysis with Gene set enrichment analysis (GSEA). ES = Enrichment Score, FDR = false discovery rate, NES = Normalized Enrichment Score. 3.7. Identification of potential molecular targeted drugs for LOXL2 Using the CellMiner drug prediction software, we identified several FDA-approved drugs that potentially target LOXL2. The analysis revealed a diverse array of therapeutic compounds with varying mechanisms of action, predominantly featuring kinase inhibitors. Among these, multi-kinase inhibitors including Lenvatinib, Dasatinib, and Pazopanib were identified, which target multiple pathways including PDGFR, FGFR, and VEGFR signaling. More selective kinase inhibitors were also predicted, such as BLU-667 (RET-specific), JNJ-42756493 (FGFR-specific), and Idelalisib (PI3K-specific). Notably, the analysis also identified non-cancer therapeutics including Zoledronate, an anti-bone resorption agent, and Simvastatin, a cholesterol-lowering drug, suggesting potential drug repurposing opportunities (Table 6). Table 6Identification of potential molecular targeted drugs for LOXL2.NameMechanismFDA statusCorrelationsP-valueBLU-667PK:RETFDA approved0.64.000LenvatinibPK:YK,PDGFR,FGFR,VEGFR,KDR,RETFDA approved0.55.000 Dasatinib BCR-ABL PK:YK,PDGFR,KITFDA approved0.51.000JNJ-42756493PK:FGFR,FGFR1,FGFR2,FGFR3,FGFR4FDA approved0.50.000ZoledronateAM NonCan:Anti-bone resorpFDA approved0.46.000MidostaurinPK:PRKCA,STK,FLT3FDA approved0.46.000 Simvastatin AM NonCan:CholFDA approved0.48.002 Everolimus PK:STK,MTORFDA approved0.40.002IdelalisibPK:PIK3FDA approved0.39.002BleomycinDbFDA approved0.38.003IPI-145PK:PIK3FDA approved0.36.005PazopanibPK:YK,PDGFR,FGFR,KIT,VEGFRFDA approved0.36.009LOXL2 = lysyl oxidase-like 2, MTOR = mammalian target of rapamycin. Identification of potential molecular targeted drugs for LOXL2. LOXL2 = lysyl oxidase-like 2, MTOR = mammalian target of rapamycin. 4. Discussions PMF is a chronic myeloproliferative neoplasm that typically indicates a poor prognosis with limited therapeutic options. Currently, allogeneic stem cell transplantation is the only curative treatment for eligible patients. The scarcity of treatment options underscores the necessity for the development of innovative therapies for PMF. PMF is a complex disease with an unclear detailed mechanism. However, exploring molecular pathogenic mechanisms can provide valuable insights. One such mechanism involves LOXL2, an enzyme involved in fibrosis and ECM remodeling. Normally, LOXL2 maintains the normal metabolism of ECM in tissues and promotes tissue repair. However, in pathological conditions such as tumors and fibrotic diseases, LOXL2 expression is abnormally elevated, leading to fibroblast activation, collagen fiber cross-linking, and increased tissue stiffness.[13,18] In this comprehensive study, we have demonstrated that LOXL2 plays a crucial role in the pathogenesis of PMF and serves as both a potential prognostic biomarker and therapeutic target. Our findings reveal multiple aspects of LOXL2’s involvement in PMF development and progression. First, we observed significantly elevated LOXL2 mRNA expression in PMF bone marrow cells, which was validated across multiple independent datasets. This consistent upregulation suggests that LOXL2 overexpression is a characteristic feature of PMF. More importantly, we found increased LOXL2 protein levels in patient serum samples, indicating that LOXL2 might serve as a readily accessible biomarker for PMF diagnosis and monitoring. The enhanced enzymatic activity of LOXL2 in PMF patients is particularly noteworthy. Unlike healthy controls where LOXL2 activity was minimal, PMF patients exhibited significantly elevated enzyme activity. This finding aligns with LOXL2’s known function in ECM modification and suggests its direct involvement in the development of bone marrow fibrosis, a hallmark of PMF. Our clinical analysis revealed strong correlations between high LOXL2 enzyme activity and adverse disease features, including higher risk scores in both IPSS and DIPSS systems. The association between elevated LOXL2 activity and increased peripheral blood blast percentages suggests its potential role in disease progression. Moreover, the identification of high LOXL2 enzyme activity as an independent adverse prognostic factor highlights its clinical significance in PMF. The GSEA results provide mechanistic insights into how LOXL2 might contribute to PMF pathogenesis. The enrichment of pathways related to ECM organization, inflammatory responses, and JAK-STAT signaling suggests that LOXL2 influences multiple aspects of the disease. The strong association with TGF-beta signaling and epithelial–mesenchymal transition pathways further supports LOXL2’s role in promoting tissue fibrosis. Additionally, the enrichment of vascular system-related pathways indicates LOXL2’s potential involvement in the abnormal bone marrow vasculature characteristic of PMF. Perhaps most promising from a therapeutic perspective is our identification of potential LOXL2-targeting drugs through CellMiner analysis. The predominance of kinase inhibitors among the predicted drugs suggests that LOXL2’s effects might be mediated through various kinase signaling pathways. The identification of both multi-kinase inhibitors and specific kinase inhibitors provides multiple potential approaches for therapeutic intervention. Recent studies have indicated that Dasatinib treatment may benefit patients with PMF, leading to significant improvements in splenomegaly, clinical symptoms, physical condition, and quality of life.[19] According to the latest research, LOXL2 is considered a potential target for the treatment of PMF. Additionally, therapeutic approaches targeting LOXL2 primarily involve modulating the tumor microenvironment, which may be a more effective strategy for treating PMF. The tumor microenvironment plays a crucial role in sustaining the continuous growth of tumor cells. In contrast to tumor cells, which exhibit a high mutation rate, the tumor microenvironment is relatively stable with fewer cellular variations, making it less prone to developing resistance against chemotherapy. Currently, treatment methods for tumors mainly focus on directly targeting the tumor cells themselves, but this approach often leads to the development of drug resistance. Therefore, targeting the tumor microenvironment may present a more effective strategy. These findings lay the foundation for further research and the development of targeted therapeutic interventions for PMF. These findings provide valuable insights for further research and may pave the way for new therapeutic approaches for patients with PMF.[10–12,20] Several limitations of our study should be noted. First, while we demonstrated correlations between LOXL2 activity and clinical features, the causal relationship needs further investigation. Second, the therapeutic potential of the identified drugs requires validation through preclinical studies and clinical trials. Third, the sample size may have been relatively small, limiting the representativeness and generalizability of the results. 5. Conclusions In summary, our study establishes LOXL2 as a key player in PMF pathogenesis. We demonstrated significantly elevated LOXL2 expression and enzymatic activity in PMF patients, with high LOXL2 activity strongly correlating with adverse clinical features and poor prognosis. Pathway analysis revealed LOXL2’s involvement in multiple PMF-relevant biological processes, including ECM remodeling and inflammatory responses. Furthermore, our drug prediction analysis identified several FDA-approved drugs as potential LOXL2-targeting therapeutics. These findings suggest LOXL2 as both a promising prognostic biomarker and therapeutic target in PMF, providing new opportunities for disease monitoring and treatment development. Author contributions Conceptualization: Guoqing Lv. Data curation: Guoqing Lv. Funding acquisition: Guoqing Lv. Investigation: Guoqing Lv. Methodology: Wenting Lv. Resources: Wenting Lv. Validation: Wenting Lv. Visualization: Wenting Lv. Writing – original draft: Wenting Lv.